Arcutis Biotherapeutics (NASDAQ:ARQT) vs. Gyre Therapeutics (NASDAQ:GYRE) Financial Review

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.

Profitability

This table compares Gyre Therapeutics and Arcutis Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gyre Therapeutics -14.80% -7.39% -5.74%
Arcutis Biotherapeutics 5.88% 14.18% 6.28%

Risk & Volatility

Gyre Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Earnings & Valuation

This table compares Gyre Therapeutics and Arcutis Biotherapeutics”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gyre Therapeutics $110.06 million 4.44 $5.03 million ($0.20) -21.20
Arcutis Biotherapeutics $376.07 million 8.86 -$16.14 million $0.21 125.51

Gyre Therapeutics has higher earnings, but lower revenue than Arcutis Biotherapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Gyre Therapeutics and Arcutis Biotherapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics 1 0 0 1 2.50
Arcutis Biotherapeutics 0 2 8 0 2.80

Arcutis Biotherapeutics has a consensus target price of $39.75, indicating a potential upside of 50.81%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Gyre Therapeutics.

Institutional and Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Gyre Therapeutics on 10 of the 15 factors compared between the two stocks.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

About Arcutis Biotherapeutics

(Get Free Report)

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.